-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the POLLUX (Daremu monoantitor/lynamine/dexamysong (D-Rd)) and CASTOR (daremu monoanti/boratezomi/dexamisund(D-Vd)) trials, Daremu monoantigen reduced the risk of progression or death in patients with recurring/refractic multiple myeloma by more than 60%.
least residual lesions (MRD) is a sensitivity detection method for disease control.
study aims to assess the correlation between persistent MRD-negative and prognosis in patients with multiple myeloma.
In both studies, MRD in patients was assessed using second-generation sequencing (10-5) at 3 and 6 months after suspected complete remission (CR), 3 and 6 months after CR (POLLUX), 6 and 12 months after the first dose, and every 12 months after CR.
consistent MRD negative (≥6 months or 12 months≥ in intentional treatment populations (ITT) ≥ CR populations.
54.8 months in patients with different MRD states and 50.2 months in CASTOR trials.
In the ITT population, MRD-negative rates were 32.5% vs 6.7% in patients treated with D-Rd vs. D-Rd vs. D-Rd and MRD negative at 15.1% vs. 1.6% (two groups of p.lt;0.0001).
MRD ≥ higher in patients who received the CR: D-Vd vs Rd=57.4% vs 29.2 (p=0.0001), D-Vd vs Vd=52.8% vs 17.4% (p=0.0035).
PFS sustained MRD-negative (12 months) patients with MRD-negative (-gt;12 months) were significantly higher in the D-Rd group who received sustained MRD-negative for more than 6 months and 12 months in the ITT population (20.3 percent) Vs 2.1% and 16.1% vs 1.4%) the proportion of patients in the ;D-Vd group who received sustained MRD-negative for more than 6 months and 12 months was also significantly higher than in the Vd group (10.4% vs 1.2% vs. 6.8% vs. 0%).
similar ≥ persistent MRD-negative results were observed in patients with CR.
more patients in the treatment group that included daremu monoantigen received MRD-negative and persistent MRD-negative, which was associated with longer progressive survival in patients.
In summary, a combination of Duremu monoantigen-based solutions induced higher sustained MRD-negative rates compared to standard therapies, while persistent MRD-negative was associated with long-lasting remission and prolonged clinical survival.
